Whitfield Represents Bristol-Myers Squibb on $90B Acquisition of Celgene Corporation

Overview

The feature reports an agreement for Bristol-Myers Squibb to acquire Celgene through a combination of shares and cash.

Transaction value

The stated enterprise value is $90 billion. This is the acquisition’s valuation measure, not legal fees, compensation to a claimant or recovered assets.

Business context

The account places the proposed combination in oncology, immunology and inflammation, and cardiovascular treatment. It says the combined portfolio would include nine products with annual sales above $1 billion.

Participants

The identified listed companies are Bristol-Myers Squibb, then NYSE: BMY, and Celgene, then NASDAQ: CELG. The feature attributes the advisory role to the source firm.